Hunan Jiudian Pharmaceutical Co. Ltd. Class A

Hunan Jiudian Pharmaceutical Co. Ltd. Class A

SSZSE:300705
10.03
CNY
-0.08
(-0.79%)
0.59EPS
18.05P/E
5.54BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.49
1.43
0.91
1.11
1.43
1.76
1.97
2.12
3.53
5.05
5.63
6.01
6.32
5.79
Basic EPS, GAAP
0.16
0.22
0.14
0.16
0.18
0.16
0.12
0.18
0.44
0.59
0.77
1.05
0.96
0.61
Free Cash Flow per Basic Share
-0.14
0.02
0.01
0.07
-0.05
-0.42
-0.19
0.16
0.14
-0.31
0.01
0.71
-0.01
- -
Dividend per Share
0.01
0.03
- -
0.04
- -
0.03
0.03
0.03
0.03
0.15
0.2
0.24
0.33
0.42
Book Value per Share
0.56
0.76
0.81
0.94
1.44
1.56
1.66
1.82
2.39
3.23
4.08
5.09
5.32
5.35
Tangible Book Value per Share
0.48
0.58
0.74
0.89
1.32
1.45
1.54
1.71
2.22
3.03
3.85
4.79
4.12
4.03
Basic Weighted Avg Shares
162
186
318
339
373
455
469
461
461
460
478
488
493
500
Sales/Revenue/Turnover
241
266
290
376
535
801
924
978
1,628
2,326
2,693
2,931
3,111
2,892
Operating Margin (%)
11.18
17.75
16.11
16.44
14.53
10.1
7.78
10.95
15.81
13.83
15.32
20.08
18.75
14.91
Depreciation Expense
7
14
11
13
16
22
37
48
54
60
71
95
124
- -
Net Income, GAAP
25
41
45
55
69
72
55
82
204
270
368
512
473
306
Effective Tax Rate (%)
12.84
14.09
9.86
12.97
10.96
9.34
6.51
9.45
9.7
7.07
8.43
10.45
10.7
16.86
Profit Margin (%)
10.47
15.47
15.37
14.49
12.83
8.98
5.96
8.41
12.55
11.59
13.68
17.48
15.2
10.59
Working Capital
71
83
119
162
439
308
254
323
650
762
1,014
1,210
1,117
1,023
LT Debt
- -
- -
- -
- -
- -
30
69
71
224
232
333
294
471
488
Total Equity
176
239
255
323
660
718
762
836
1,099
1,553
1,973
2,527
2,786
2,824
Return on Invested Capital (%)
- -
16.68
15.49
17.17
13.09
9.84
6.88
9.07
17.24
16.41
17.1
19.83
15.54
9.19
Return on Capital (%)
- -
18.35
17.2
18.02
13.73
10.01
6.99
9.53
18.6
17.4
17.88
20.38
15.92
10.34
Return on Common Equity (%)
- -
19.87
18.08
18.87
13.94
10.45
7.44
10.3
21.11
20.34
20.89
22.77
18.24
11.64

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
66
192
262
LT Borrowings
505
484
488
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
500
500
500
Market Capitalization
6,924
4,893
5,538

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,545
1,540
1,738
Cash, Cash Equivalents & STI
620
566
755
Accounts Receivable, Net
296
288
293
Inventories
380
435
462
Total Current Liabilities
414
575
715
Payables & Accruals
- -
- -
- -
ST Debt
66
192
262
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.39%
27.64%
10.27%
Free Cash Flow
874.36%
1,468.72%
-101.67%
Net Income, GAAP
32.7%
49.66%
-7.72%
Sales/Revenue/Turnover
28.27%
28.01%
6.15%
Total Cash Common Dividend
393.65%
93.71%
39.07%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
591
775
780
785
2,931
2025
696
816
- -
843
3,111
2026
595
692
762
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.36
0.33
0.34
0.13
1.05
2025
0.25
0.34
- -
0.13
0.96
2026
0.11
0.21
0.16
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.23
- -
- -
0.24
2025
- -
0.31
- -
- -
0.33
2026
- -
0.41
0.01
- -
- -

Company Description

CEO
Yang Yang
Full Time Employees
2,298
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building A1, Shibuya Science and Technology Industrial Park Changsha HU China 410205
IPO Date
Oct 10, 2017
Business
Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) researches, develops, produces, and sells pharmaceutical products including finished dosage forms, active pharmaceutical ingredients (APIs), excipients, Chinese traditional medicines, and nutritional supplements primarily in China and internationally; its core offerings encompass analgesic drugs such as loxoprofen sodium gel plaster and ketoprofen gel plaster, cardio-cerebrovascular medications like rosuvastatin calcium tablets, anti-infective agents, anti-allergic products including ebastine tablets, digestive system treatments such as pantoprazole sodium enteric tablets and rabeprazole sodium enteric tablets, urinary system drugs, respiratory medicines, gynecological products, and supplements like ferrous succinate tablets and acetylcysteine granules, with 24 finished products having passed drug consistency evaluation and specialized capabilities in high-end formulations including transdermal drug delivery, controlled release, tablets, capsules, granules, oral solutions, syrups, suspensions, cataplasms, and injections; the company also provides CMO/CDMO services and operates through subsidiaries such as Hunan Jiudian Hongyang Pharmaceutical Co., Ltd. for APIs and excipients, Hunan Pudao Pharmaceutical Technology Co., Ltd. for CXO services, and others focused on wholesale, retail, and e-commerce of medicines. Founded in 2001 and headquartered in Changsha, Hunan Province, China, the company employs nearly 1,900 people, maintains multiple GMP-certified production lines, and exports to over 60 countries including the US, South Korea, and Europe, targeting hospitals, pharmacy chains, and global clients with a focus on high-tech generic drugs, innovative drugs, patented medicines, and percutaneous administration platforms. Recent developments include ranking 76th on the Hunan Top 100 Manufacturing Enterprises list in 2024, a record high reflecting innovation-driven growth and annual sales of nearly 1.6 billion yuan from core anti-inflammatory patches; obtaining a registration certificate in 2025 for polyacrylic acid solution pharmaceutical excipient from its subsidiary Jiudian Hongyang; securing clinical trial approval for PDX-04 in acute gout attacks and a drug registration certificate for a gastric ulcer treatment; completing clinical research and production filing for innovative TCM drug Jiaoqi Zhitong Gel Patch alongside chemical drug advancements; inking a strategic licensing deal in early 2024 with Zonsen PepLib Biotech for preclinical dual-functional peptide PL054 offering up to 560 million yuan in milestones; proposing to acquire a 10% stake in Nuona Pharmaceuticals using 46.58 million yuan to strengthen control; forming a strategic cooperation with Jinying Jiahe for health consulting; passing joint inspections by Fujian and Hunan drug administrations in 2025; and expanding global partnerships at CPHI Shanghai 2025 while advancing intelligent manufacturing as a Hunan Advanced-Level Intelligent Factory.